9 results
  • A021703 SOLARIS

    Randomized double-blind phase III trial of vitamin D3 supplementation in patients with previously untreated metastatic colorectal cancer (SOLARIS)

    For inquiries, call (732) 557-8294
    • Community Medical Center
  • NOVA TRIAL

    Evaluation of the Performance of the Clinical Genomics Colvera Test in the Detection of Disease Recurrence in Patients Diagnosed with Colorectal Cancer

    To access the full protocols, please contact: Mary Danish, RN, Oncology Clinical Research Coordinator Mary.Danish@rwjbh.org or call (732) 923-6564.

    For inquiries, call (732) 923-6564
    • Robert Wood Johnson University Hospital
  • NRG-GI005

    Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

    For inquiries, call (732) 557-8294
    • Community Medical Center
  • RCINJ 071818 IS0-CC-007

    A Randomized, Multicenter, Parallel-Group, Phase III Study to Compare the Efficacy of Arfolitixorin versus Leucovorin in Combination with 5-Fluorouracil,Oxaliplatin, and Bevacizumab in Patients with Advanced Colorectal Cancer.

    Key Inclusion:

    • Colorectal adenocarcinoma with material for gene expression analysis
    • Non-resectable mCRC planned for firest line with 5-FU, oxaliplatin, and bevacizumab

    ***NOTE: MVASI NOT PERMITTED ***

    Treatment:

    ARFOX vs mFOLFOX-6
     

    Principal Investigator: Delia Radovich, MD

    For inquiries, call (973) 322-2470
    • Saint Barnabas Medical Center
  • RCINJ 072005 FRESCO-2

    A GLOBAL, MULTICENTER, RANDOMIZED, PLACEBOCONTROLLED PHASE 3 TRIAL TO COMPARE THE EFFICACY AND SAFETY OF FRUQUINTINIB PLUS BEST SUPPORTIVE CARE TO PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (FRESCO-2)

    Key Inclusion:

    •  mCRC – adenocarcinoma
    •  Progressed on or been intolerant to either TAS-102 oe regorafenib.
    •  Subjects who received oxaliplatin in the adjuvant setting must have progressed within 6 months of completion of adjuvant therapy.

    For inquiries, call (973) 322-2470
    • Saint Barnabas Medical Center
  • Rutgers Cancer Institute of New Jersey - Colon Cancer Trials

    View Trials

    • Rutgers Cancer Institute of New Jersey
  • TAS-OX for Refractory Metastatic Colon Cancer

    TAS-102 In Combination with Oxaliplatin (TAS-OX) for Refractory Metastatic Colorectal Cancer.

    Key Inclusion Criteria

    • Histologically confirmed stage IV colon cancer (AJCC 7th edition) that has progressed after standard therapy that included 5-FU, irinotecan and oxaliplatin. Patients who could not tolerate standard agents because of unacceptable, but reversible toxicity necessitating their discontinuation will be allowed to participate.
    • Patients who had received adjuvant chemotherapy and had recurrence during or within 6 months of completion of the adjuvant chemotherapy will be allowed to count the adjuvant therapy as one chemotherapy regimen.
    • Presence of measurable disease
    • RAS mutation and MMR status must be determined (or tissue availability for testing if not already determined).
    • ECOG 0-1.

    Key Exclusion Criteria

    1. Patients who have previously received TAS-102.
    2. Grade 2 or higher peripheral neuropathy (functional impairment).
    3. Symptomatic CNS metastases requiring treatment.
    4. Other active malignancy within the last 3 years (except for non-melanoma skin cancer or a non-invasive/in situ cancer).
    5. Major surgery within prior 4 weeks.
    6. Any anticancer therapy within prior 3 weeks of first dose of study drug.

    TAS-102
    On Day 1-5 of each 14 day cycle TAS-102 (35 mg/m2/dose) will be taken orally 2 times daily (between 8 and 12 hours) -

    Oxaliplatin
    Oxaliplatin 85mg/m2 will be given as a chemo infusion on Day 1 of 14 day cycle
     

    Principal Investigator: Delia Radovich, MD

    For inquiries, call (973) 322-2470
    • Saint Barnabas Medical Center
  • TAS-Ox RCINJ 071801

    TAS-102 In Combination with Oxaliplatin (TAS-OX) for Refractory Metastatic Colorectal Cancer.

    Key Inclusion Criteria

    • Histologically confirmed stage IV colon cancer (AJCC 7th edition) that has progressed after standard therapy that included 5-FU, irinotecan and oxaliplatin. Patients who could not tolerate standard agents because of unacceptable, but reversible toxicity necessitating their discontinuation will be allowed to participate.
    • Patients who had received adjuvant chemotherapy and had recurrence during or within 6 months of completion of the adjuvant chemotherapy will be allowed to count the adjuvant therapy as one chemotherapy regimen.
    • Presence of measurable disease
    • RAS mutation and MMR status must be determined (or tissue availability for testing if not already determined).
    • ECOG 0-1.

    Key Exclusion Criteria

    1.  Patients who have previously received TAS-102.
    2.  Grade 2 or higher peripheral neuropathy (functional impairment).
    3.  Symptomatic CNS metastases requiring treatment.
    4.  Other active malignancy within the last 3 years (except for non-melanoma skin cancer or a non-invasive/in situ cancer).
    5.  Major surgery within prior 4 weeks.
    6.  Any anticancer therapy within prior 3 weeks of first dose of study drug.

    TAS-102
    On Day 1-5 of each 14 day cycle TAS-102 (35 mg/m2/dose) will be taken orally 2 times daily (between 8 and 12 hours) -

    Oxaliplatin
    Oxaliplatin 85mg/m2 will be given as a chemo infusion on Day 1 of 14 day cycle
     

    For inquiries, call (973) 322-2470
    • Saint Barnabas Medical Center
  • The Cancer Experience Registry

    An online project where patients and caregivers participate in survey based research.

    For more information in regards to clinical research, please contact: Mary Danish, RN, Oncology Clinical Research Coordinator Mary.Danish@rwjbh.org or call (732) 923-6564.

    For inquiries, call (732) 923-6564
    • Monmouth Medical Center
    • Robert Wood Johnson University Hospital